Radient Pharmaceuticals (RPC) Tops Q2 EPS by 1c
Tweet
Share
E-mailGet Alerts RPC Hot Sheet
Join SI Premium – FREE
Radient Pharmaceuticals (NYSE: RPC) reported Q2 EPS of $0.24, $0.01 better than the analyst estimate of $0.23. Revenue for the quarter came in at $80.9 million versus the consensus estimate of $79.89 million.
For earnings history and earnings-related data on Radient Pharmaceuticals (RPC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kepler Cheuvreux Downgrades Volkswagen AG (VOW:GR) (VWAGY) to Hold
- Rothschild Redburn Starts Digital Realty Trust (DLR) at Buy
- Canaccord Starts L1 Group Ltd (L1G:AU) at Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
